News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
278,846 Results
Type
Article (14498)
Company Profile (101)
Press Release (264246)
Multimedia
Podcasts (71)
Webinars (14)
Section
Business (88569)
Career Advice (468)
Deals (15508)
Drug Delivery (82)
Drug Development (36848)
Employer Resources (50)
FDA (6437)
Job Trends (6266)
News (151274)
Policy (14167)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (455)
Accelerated approval (25)
ADA (10)
Adcomms (9)
Allergies (98)
Alliances (23359)
ALS (72)
Alzheimer's disease (523)
Antibody-drug conjugate (ADC) (162)
Approvals (6742)
Artificial intelligence (273)
ASCO (113)
Autoimmune disease (78)
Automation (21)
Bankruptcy (151)
Best Places to Work (4377)
BIOSECURE Act (9)
Biosimilars (152)
Biotechnology (39)
Bladder cancer (51)
Brain cancer (40)
Breast cancer (210)
Cancer (1727)
Cardiovascular disease (203)
Career advice (422)
Career pathing (14)
CAR-T (66)
CDC (7)
Cell therapy (199)
Cervical cancer (20)
Clinical research (32650)
Collaboration (949)
Commercialization (1)
Company closure (1)
Compensation (399)
Complete response letters (46)
COVID-19 (793)
CRISPR (54)
C-suite (641)
Cystic fibrosis (61)
Data (2546)
Decentralized trials (1)
Denatured (19)
Depression (59)
Dermatology (15)
Diabetes (167)
Diagnostics (1458)
Digital health (16)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (163)
Drug pricing (122)
Drug shortages (15)
Duchenne muscular dystrophy (99)
Earnings (34311)
Editorial (24)
Employer branding (4)
Employer resources (46)
Events (40049)
Executive appointments (612)
FDA (7835)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (552)
Gene editing (86)
Generative AI (27)
Gene therapy (202)
GLP-1 (492)
Government (1433)
Grass and pollen (4)
Guidances (173)
Healthcare (3655)
Hematology (66)
HIV (17)
Huntington's disease (12)
IgA nephropathy (52)
Immunology and inflammation (84)
Immuno-oncology (30)
Indications (96)
Infectious disease (892)
Inflammatory bowel disease (86)
Inflation Reduction Act (7)
Influenza (29)
Intellectual property (138)
Interviews (60)
IPO (5950)
IRA (33)
Job creations (2073)
Job search strategy (375)
JPM (29)
Kidney cancer (12)
Labor market (36)
Layoffs (211)
Leadership (10)
Legal (3459)
Liver cancer (26)
Longevity (10)
Lung cancer (236)
Lymphoma (159)
Machine learning (15)
Management (17)
Manufacturing (562)
Marketing (1)
MASH (92)
Medical affairs (1)
Medical device (1398)
Medtech (1413)
Mergers & acquisitions (10090)
Metabolic disorders (569)
mRNA (63)
Multiple sclerosis (59)
NASH (15)
Neurodegenerative disease (110)
Neuropsychiatric disorders (48)
Neuroscience (1058)
Neurotech (1)
NextGen: Class of 2026 (1595)
Non-profit (615)
Now hiring (24)
Obesity (291)
Opinion (151)
Ovarian cancer (65)
Pain (136)
Pancreatic cancer (71)
Parkinson's disease (110)
Partnered (12)
Patents (279)
Patient recruitment (173)
Peanut (15)
People (30287)
Pharmaceutical (60)
Pharmacy benefit managers (19)
Phase 1 (8457)
Phase 2 (13807)
Phase 3 (12446)
Pipeline (3493)
Policy (148)
Postmarket research (1403)
Preclinical (3415)
Press Release (25)
Prostate cancer (114)
Psychedelics (22)
Radiopharmaceuticals (160)
Rare diseases (470)
Real estate (2676)
Recruiting (19)
Regulatory (11414)
Reports (16)
Research institute (584)
Resumes & cover letters (56)
Rett syndrome (11)
RNA editing (9)
RSV (25)
Schizophrenia (87)
Series A (115)
Series B (64)
Service/supplier (2)
Sickle cell disease (55)
Special edition (11)
Spinal muscular atrophy (85)
Sponsored (11)
Startups (1658)
State (2)
Stomach cancer (6)
Supply chain (64)
Tariffs (71)
The Weekly (50)
Vaccines (273)
Venture capital (40)
Weight loss (172)
Women's health (49)
Worklife (4)
Date
Today (35)
Last 7 days (184)
Last 30 days (898)
Last 365 days (10383)
2026 (5221)
2025 (10729)
2024 (12526)
2023 (14292)
2022 (19617)
2021 (20129)
2020 (19095)
2019 (14922)
2018 (11756)
2017 (13933)
2016 (13159)
2015 (15499)
2014 (12447)
2013 (10614)
2012 (11424)
2011 (11965)
2010 (10939)
Location
Africa (324)
Alabama (20)
Alaska (1)
Arizona (89)
Arkansas (4)
Asia (21269)
Australia (2743)
California (3936)
Canada (1789)
China (745)
Colorado (175)
Connecticut (155)
Delaware (168)
Europe (41733)
Florida (749)
Georgia (77)
Hawaii (1)
Idaho (11)
Illinois (460)
India (66)
Indiana (306)
Iowa (2)
Japan (351)
Kansas (84)
Kentucky (21)
Louisiana (7)
Maine (2)
Maryland (501)
Massachusetts (3200)
Michigan (58)
Minnesota (206)
Mississippi (1)
Missouri (38)
Montana (9)
Nebraska (8)
Nevada (19)
New Hampshire (11)
New Jersey (1754)
New Mexico (7)
New York (1133)
North Carolina (740)
North Dakota (2)
Northern California (1864)
Ohio (94)
Oklahoma (5)
Oregon (18)
Pennsylvania (854)
Puerto Rico (18)
Rhode Island (18)
South America (508)
South Carolina (11)
Southern California (1729)
Tennessee (66)
Texas (560)
United States (15642)
Utah (66)
Vermont (1)
Virginia (209)
Washington D.C. (42)
Washington State (288)
West Virginia (1)
Wisconsin (50)
Wyoming (1)
278,846 Results for "kala pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New “AutoResearch” Milestone Signals the Rise of Autonomous Research Agents
Open-source breakthrough demonstrates AI agents can run 100+ experiments overnight-reinforcing the agentic R&D paradigm Researgency.ai is bringing to life sciences with Kala Bio (KALA)
March 11, 2026
·
6 min read
Press Releases
KALA BIO Announces Reverse Stock Split - May 7, 2026
May 7, 2026
·
6 min read
Press Releases
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
April 1, 2026
·
8 min read
Press Releases
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”
March 4, 2026
·
20 min read
Press Releases
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
December 2, 2025
·
5 min read
Press Releases
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
December 8, 2025
·
3 min read
Press Releases
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
September 3, 2025
·
6 min read
Press Releases
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
September 4, 2025
·
1 min read
Press Releases
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 11, 2025
·
12 min read
Genetown
Kala Pharmaceuticals Announces Name Change to KALA BIO
Kala Pharmaceuticals, Inc. today announced that it will change its name to KALA BIO, Inc. effective August 2, 2023, to better reflect the company’s focus on advancing biologics for the treatment of ophthalmic conditions.
August 2, 2023
·
5 min read
1 of 27,885
Next
